Impact News +++ Corporate News: Rubean AG (EQS) +++ RUBEAN Aktie +3,40%

TEMPRAMED Aktie

>TEMPRAMED Aktienkurs

0.376 EUR -5.1% (TradegateBSX)

Ask: 0.376 EUR / 2654 Stück

Bid: 0.352 EUR / 2847 Stück

Tagesumsatz: 20 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TEMPRAMED Aktie über LYNX handeln

Intraday

1 Jahr

>TEMPRAMED Performance

1 Woche: +6,0%

1 Monat: -2,6%

3 Monate: -15,3%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>TEMPRAMED Aktie

Name:

TEMPRAMED TECHNOLOGIES LTD.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA88024B1022 / A41JQU

Symbol/ Ticker:

9DY (Frankfurt)

Kürzel:

FRA:9DY, ETR:9DY, 9DY:GR

Index:

Webseite:

https://tempramed.com/

Profil:

TempraMed Technologies Ltd. is a medical device technology company specializing in patent-protected solutions for temperature-sensitive medications. Its primary focus is revolutionizing injectors and storage for medications like insulin by making the..
>Volltext..

Marktkapitalisierung:

26.59 Mio. EUR

Unternehmenswert:

27.4 Mio. EUR

Umsatz:

1.04 Mio. EUR

EBITDA:

-4.89 Mio. EUR

Nettogewinn:

-16.6 Mio. EUR

Gewinn je Aktie:

-0.22 EUR

Schulden:

1 Mio. EUR

Liquide Mittel:

0.19 Mio. EUR

Operativer Cashflow:

Bargeldquote:

0.09

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TEMPRAMED

Letzte Datenerhebung:

01.07.26

>TEMPRAMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 78.46 Mio. St.

Frei handelbar: 65.86%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 25.83

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 36.88%

Gewinnmarge: -1595.51%

Operative Marge: -475.65%

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>TEMPRAMED Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Stoffwechselerkrankungen (Diabetes/ Adipositas)

>TEMPRAMED Chart & Kurs - Tradegate

>TEMPRAMED News

30.06.26 - 09:18	TempraMed Technologies Ltd.: TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is ......

26.06.26 - 22:18	TempraMed Technologies Ltd.: TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-......

04.06.26 - 13:12	TempraMed Technologies Ltd.: TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally (Newsfile)
	HighlightsTempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and tem......

22.05.26 - 18:06	TempraMed Technologies Ltd.: TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how te......

14.05.26 - 09:06	TempraMed meldet die Erteilung eines indischen Designpatents für sein VIVI Cap Smart-Produkt (IRW Press)
	Ein weiterer wichtiger Meilenstein in der kontinuierlichen globalen IP-Strategie, der den Schutz von VIVI Cap Smart auf internationalen Märkten erweitert Highlights - Das erteilte Patent......

14.05.26 - 09:06	TempraMed Technologies Ltd.: TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product (Newsfile)
	HighlightsGranted Patent covers the design of VIVI Cap Smart across major international, growing marketStrengthens the Company's intellectual property position in one of the world's largest health......

29.04.26 - 22:42	TempraMed Technologies Ltd.: TempraMed Announces Continuance into Ontario (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how ......

07.04.26 - 13:06	TempraMed Technologies Ltd.: TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product (Newsfile)
	HighlightsBrazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box multi-medication storage platform expected to market end of 2......

30.03.26 - 13:12	TempraMed Technologies Ltd.: TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how ......

24.03.26 - 12:12	TempraMed Technologies Ltd.: TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box (Newsfile)
	HighlightsChinese patent officially granted by CNIPA on March 17, 2026Covers core innovations underpinning TempraMed's VIVI Box multi-medication storage platform expected to market end of 2026Stre......

11.03.26 - 12:06	TempraMed Technologies Ltd.: TempraMed′s Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how ......

26.02.26 - 13:12	TempraMed Technologies Ltd.: TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming h......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Gott kann nichts logisch Unmögliches tun, doch setzt dies seiner Allmacht keine Grenzen. Er kann nichts Absurdes tun oder erfinden. - Leszek Kolakowski

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram